Please login to the form below

Not currently logged in
Email:
Password:

BMS-986205

This page shows the latest BMS-986205 news and features for those working in and with pharma, biotech and healthcare.

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

Suspends enrolment in BMS-986205 trials for NSCLC and head and neck cancer. ... Bristol-Myers Squibb hammered another nail in the coffin of IDO1 as a drug target in immuno-oncology yesterday after halting two trials of its BMS-986205 candidate acquired

Latest news

  • BMS boosts immuno-oncology with $2.3bn IFM buy BMS boosts immuno-oncology with $2.3bn IFM buy

    The big pharma has steadily added to its portfolio with a stream of candidates targeting molecules such as CD137 (urelumab), IDO (BMS-986205), and LAG-3 (BMS-986016) - all in phase ... Adding the new candidates "broadens our ability to investigate

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics